There are 363 resources available
209P_PR - Understanding patient experience in Europe: the first Global Lung Cancer Coalition Patient Experience Survey
Presenter: Vanessa Beattie
Session: e-Poster Display Session
118P - The clinical utility of advanced lung inflammation index (ALI) for immunotherapy guidance in non-small-cell lung cancer
Presenter: Giannis Mountzios
Session: e-Poster Display Session
119P - The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced Non-small cell lung cancer (aNSCLC) patients (pts)
Presenter: Alessandro Dal Maso
Session: e-Poster Display Session
121P - RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Analysis of RAS and NF1 Co-Mutations in Advanced NSCLC
Presenter: Helen Adderley
Session: e-Poster Display Session
122P - STK11 and/or KEAP1 mutations and outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic literature review.
Presenter: Alberto Codima
Session: e-Poster Display Session
127P - Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICI).
Presenter: Patricia Iranzo
Session: e-Poster Display Session
59P - Patterns of recurrence and survival after complete resection of pathological stage N2 small-cell lung cancer
Presenter: Lian y
Session: e-Poster Display Session
135P - The real-world use of Tyrosine Kinase Inhibitors (TKIs) in Epidermal Growth Factor Receptor mutated (EGFRm) advanced (stage IIIb / IIIc / IV) Non-Small Cell Lung Cancer (NSCLC) patients
Presenter: Janakiraman Subramanian
Session: e-Poster Display Session
137P - Epidermal Growth Factor Receptor mutation status and response to Tyrosine Kinase Inhibitors in advanced Chinese female lung squamous cell carcinoma: a retrospective study
Presenter: Qing Chang
Session: e-Poster Display Session
139P - The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy - Real world data from two certified lung cancer centers in Germany
Presenter: Julia Roeper
Session: e-Poster Display Session